IL17A and COVID-19: Therefore, the current in silico findings using network pharmacology uncovered all pharmacological targets, functions and signalling pathways of puerarin to treat COVID‐19, marked by inhibition of cytonecrosis‐ and inflammation‐associated signalling pathways, such as the IL‐17 signalling pathway, TNF signalling pathway, MAPK signalling pathway and HIF‐1 signalling pathway.